Seagen, Inc. (SGEN)
Stock Price:
$165.89 USD
-2.18 (-1.30%)
Updated November 24, 12:43 PM EST - Market open
Key Info
| Market Cap |
29.91B |
| Revenue (ttm) |
1.86B |
| Net Income (ttm) |
472.41M |
| Shares Out |
180.31M |
| EPS (ttm) |
2.65 |
| PE Ratio |
62.60 |
| Forward PE |
625.00 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 24 |
| Last Price |
$165.89 |
| Previous Close |
$168.07 |
| Change ($) |
-2.18 |
| Change (%) |
-1.30% |
| Day's Open |
167.82 |
| Day's Range |
164.40 - 168.38 |
| Day's Volume |
305,126 |
| 52-Week Range |
90.57 - 213.94 |
More Stats
| Market Cap |
29.91B |
| Enterprise Value |
28.26B |
| Earnings Date (est) |
Feb 11, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
180.31M |
| Float |
178.35M |
| EPS (basic) |
2.72 |
| EPS (diluted) |
2.65 |
| FCF / Share |
3.27 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
1.60% |
| FCF Yield |
1.91% |
| Payout Ratio |
n/a |
| Shares Short |
3.50M |
| Short Ratio |
4.24 |
| Short % of Float |
1.96% |
| Beta |
1.20 |
| PE Ratio |
62.60 |
| Forward PE |
625.00 |
| P/FCF Ratio |
52.41 |
| PS Ratio |
16.05 |
| PB Ratio |
13.75 |
| Revenue |
1.86B |
| Operating Income |
393.45M |
| Net Income |
472.41M |
| Free Cash Flow |
570.68M |
| Net Cash |
1.65B |
| Net Cash / Share |
9.17 |
| Gross Margin |
8.23% |
| Operating Margin |
21.11% |
| Profit Margin |
25.30% |
| FCF Margin |
30.62% |
| ROA |
9.64% |
| ROE |
23.40% |
| ROIC |
37.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (20)
| Buy |
12 |
| Overweight |
0 |
| Hold |
7 |
| Underweight |
1 |
| Sell |
0 |
Price Target
$201.94*
(21.73% upside)
Low
165
Current: $165.89
High
254
Target: 201.94
*Average 12-month price target from 17 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 917 | 655 | 482 | 418 | 337 | 287 | 269 | 211 | 94.78 | 107 |
| Revenue Growth | 40.02% | 35.76% | 15.33% | 24.15% | 17.45% | 6.5% | 27.73% | 122.43% | -11.81% | - |
| Gross Profit | 873 | 566 | 428 | 376 | 299 | 258 | 248 | 197 | 91.66 | 107 |
| Operating Income | -221 | -260 | -196 | -143 | -121 | -77.36 | -62.86 | -57.25 | -144 | -68.20 |
| Net Income | -159 | -223 | -126 | -140 | -120 | -76.14 | -62.52 | -53.78 | -152 | -66.27 |
| Shares Outstanding | 165 | 158 | 143 | 141 | 129 | 123 | 122 | 118 | 113 | 101 |
| Earnings Per Share | -0.96 | -1.41 | -0.88 | -1.00 | -0.93 | -0.62 | -0.51 | -0.46 | -1.34 | -0.66 |
| Operating Cash Flow | -164 | -204 | -119 | -96.97 | -133 | -60.00 | -1.11 | 10.88 | -124 | 6.81 |
| Capital Expenditures | -70.75 | -21.22 | -70.38 | -27.84 | -13.39 | -17.18 | -22.15 | -10.49 | -11.25 | -3.55 |
| Free Cash Flow | -234 | -225 | -189 | -125 | -147 | -77.18 | -23.26 | 0.40 | -135 | 3.26 |
| Cash & Equivalents | 811 | 411 | 413 | 589 | 650 | 313 | 374 | 364 | 331 | 282 |
| Total Debt | 67.61 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 743 | 411 | 413 | 589 | 650 | 313 | 374 | 364 | 331 | 282 |
| Assets | 2,206 | 1,503 | 878 | 838 | 895 | 459 | 484 | 471 | 425 | 330 |
| Liabilities | 330 | 229 | 200 | 204 | 209 | 248 | 254 | 245 | 206 | 168 |
| Book Value | 1,876 | 1,274 | 678 | 634 | 686 | 211 | 230 | 226 | 219 | 162 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Seagen, Inc. |
| Country |
United States |
| Employees |
1,605 |
| CEO |
Clay B. Siegall |
Stock Information
| Ticker Symbol |
SGEN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SGEN |
Description
Seagen, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; biotechnology and pharmaceutical companies; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.